马德里格尔制药 MDGL
$399.63 −$0.47 (-0.12%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $403.28 +0.91%
开盘$400.00
昨收$400.10
当日区间$378.28 – $401.61
成交量1.09M
市值$9.28B
市盈率（TTM）–
股息率–
MDGL 相关新闻
匹配 Madrigal Pharmaceuticals 或代码 MDGL 的头条新闻，按最新排序。
- Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962
- Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 25.83 Million in Common Stocks
- Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704 正面
- Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725
- Wolfe Research Upgrades Madrigal Pharmaceuticals(MDGL.US) to Buy Rating, Announces Target Price $605 正面
- Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $962 负面
- CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $612 正面
- Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $709
- TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $644
- H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620
- Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, Vs. FactSet Est of $352.1M
- CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $587 正面
- Wells Fargo Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $685
- UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669
- BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 正面
暂无评论——快来第一个聊聊 MDGL。
登录后参与讨论。